Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations

被引：0
|
作者：
Ros Montana, F. J. [1 ]
Navarro, V. [2 ]
Comas, R. [2 ]
Landolfi, S. [3 ]
Ramirez, L. [4 ]
Palmer, H. G. [1 ]
Garcia Rodriguez, A. [1 ]
Saoudi Gonzalez, N. [1 ]
Baraibar Argota, I. [1 ]
Rodriguez Castells, M. [5 ]
Salva Ballabrera, F. [6 ]
Tabernero, J. [7 ]
Elez Fernandez, M. E. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Cellex Ctr, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Stem Cells Lab, Cellex Ctr, Barcelona, Spain
[5] Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Cellex Ctr, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Med Oncol Gastrointestinal Unit, Barcelona, Spain
[7] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
626P
引用
收藏
页码：S447 / S447
页数：1
相关论文
共 50 条
  • [41] Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
    Cremolini, Chiara
    Pietrantonio, Filippo
    Tomasello, Gianluca
    Dadduzio, Vincenzo
    Moretto, Roberto
    Morano, Federica
    Schirripa, Marta
    Antoniotti, Carlotta
    Fuca, Giovanni
    Bergamo, Francesca
    Rossini, Daniele
    Nichetti, Federico
    Ziampiri, Stamatia
    Ghidini, Michele
    Marmorino, Federica
    Prisciandaro, Michele
    Falcone, Alfredo
    De Braud, Filippo
    Loupakis, Fotios
    Lonardi, Sara
    ESMO OPEN, 2017, 2 (03)
  • [42] Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
    Qiu, M.
    Wei, G.
    Leng, W.
    Cao, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S446 - S446
  • [43] BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
    Moisset, Laure
    Raimbourg, Judith
    Hiret, Sandrine
    Dauve, Jonathan
    Boisdron-Celle, Michele
    Senellart, Helene
    Raoul, Jean-Luc
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 426 - 429
  • [44] BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version
    Hummel, Michael
    Hegewisch-Becker, Susanna
    Neumann, Jens
    Vogel, Arndt
    PATHOLOGE, 2021, 42 (06): : 578 - 590
  • [45] Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Marks, Asher M.
    Bindra, Ranjit S.
    DiLuna, Michael L.
    Huttner, Anita
    Jairam, Vikram
    Kahle, Kristopher T.
    Kieran, Mark W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [46] Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.
    Chu, Jenny E.
    Johnson, Benny
    Morris, Van K.
    Raghav, Kanwal Pratap Singh
    Swanson, Lucas
    Lim, Howard John
    Renouf, Daniel John
    Gill, Sharlene
    Wolber, Robert
    Karsan, Aly
    Schaeffer, David F.
    Kopetz, Scott
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAF V600E-Mutated Thyroid Cancer
    Jeon, Youngkyung
    Park, Sehhoon
    Lee, Se-Hoon
    Kim, Tae Hyuk
    Kim, Sun Wook
    Ahn, Myung-Ju
    Jung, Hyun Ae
    Chung, Jae Hoon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1270 - 1276
  • [48] Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Kopetz, S.
    Murphy, D. A.
    Pu, J.
    Yaeger, R.
    Ciardiello, F.
    Desai, J.
    Van Cutsem, E.
    Wasan, H. S.
    Yoshino, T.
    Alkuzweny, B.
    Xie, T.
    Zhang, X.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S681 - S682
  • [49] REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY
    Zapotocky, Michal
    Ryall, Scott
    Fukuoka, Kohei
    Stucklin, Ana Guerreiro
    Bennett, Julie
    Sumerauer, David
    Pavelka, Zdenek
    Cruz, Ofelia
    Solano, Palma
    Garre, Maria Luisa
    Hauser, Peter
    Frappaz, Didier
    Hansford, Jordan
    Amayiri, Nisreen
    Morse, Helena
    Sabel, Magnus
    Bechensteen, Anne Grete
    Su, Jack
    Karajannis, Matthias
    Finlay, Jonathan
    Eisenstat, David
    Canete, Adela
    Toledano, Helen
    Dahiya, Sonika
    Leary, Sarah
    Nicolaides, Theodore
    Finch, Elisabeth
    Mueller, Sabine
    Levy, Jean Mulcahy
    Ellison, David
    Lassaletta, Alvaro
    Larouche, Valerie
    Ramaswamy, Vijay
    Dirks, Peter
    McKeown, Tara
    Bartels, Ute
    Bouffet, Eric
    Hawkins, Cynthia
    Tabori, Uri
    NEURO-ONCOLOGY, 2018, 20 : 117 - 117
  • [50] Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution
    Perez Velasco, R.
    Macias Rodriguez, P.
    Garcia Grove, C.
    Martin Sanchez, D.
    Torrado, C.
    Barroso, A.
    Tallafigo, F.
    Monescillo, E.
    Buezas Perez, R.
    Torres Sempere, J.
    Pereira Vicente, A.
    Valladares-Ayerbes, M.
    Lopez Ladron, A.
    Rodriguez, J.
    Limon, L.
    Gallego Jimenez, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S64 - S64
12345